Syndecan-1 (sCD138) levels in chronic lymphocytic leukemia: clinical and hematological correlations

Monica Sharma,Seema Tyagi,Preeti Tripathi,Tulika Seth 대한혈액학회 2018 Blood Research Vol.53 No.3

Background Syndecan-1 (sCD138) has recently been suggested to predict the clinical course of ear-ly-stage chronic lymphocytic leukemia (CLL), but few studies have been reported. This study assessed the role of syndecan-1 in the prognosis of patients with CLL and its correla-tion with other prognostic markers. Methods This prospective study was performed in the hematology department of an Indian tertiary care center, over nineteen months (Jun. 2009‒Jan. 2011). Forty-nine new patients with CLL presented during this period and were included. Twenty age- and gender-matched healthy patients served as controls, and six patients with multiple myeloma were included as positive controls. Baseline serum syndecan-1 concentrations were measured for all patients at presentation using ELISA (Diaclone, Besancon, France). At baseline, patients were divided into low (N=10), intermediate (N=18) and high (N=21) risk cohorts. Serum syndecan-1 levels in these patient subgroups were compared with clinical and laboratory parameters. Results The median syndecan-1 level in patients with CLL (73.32 ng/mL, range, 28.71‒268.0 ng/mL) was marginally higher than that in healthy patients (63.10 ng/mL, range, 55.0‒75.11 ng/mL). At presentation, syndecan-1 levels in patients with CLL correlated strongly with symptomatic disease (cytopenias, P=0.004) and higher clinical stage (Rai stage III and IV, P=0.001) markers and poorly with 2-microglobulin level (P=0.270), diffuse BM infiltration (P=0.882), and surrogate mutation status markers (CD 38, P=0.174 and ZAP-70, P=0.459). Syndecan-1 levels dichotomized by the median value were higher with progressive disease markers, e.g. shorter lymphocyte doubling time (LDT, P=0.015) and increased treatment (P=0.099). ConclusionIn CLL, serum syndecan-1 (sCD138) levels at presentation correlate with disease burden, and higher baseline levels may predict early treatment.

Syndecan-1 (sCD138) levels in chronic lymphocytic leukemia: clinical and hematological correlations

Monica Sharma,Seema Tyagi,Preeti Tripathi,Tulika Seth 대한혈액학회 2018 Blood Research Vol.53 No.3

Background Syndecan-1 (sCD138) has recently been suggested to predict the clinical course of ear-ly-stage chronic lymphocytic leukemia (CLL), but few studies have been reported. This study assessed the role of syndecan-1 in the prognosis of patients with CLL and its correla-tion with other prognostic markers. Methods This prospective study was performed in the hematology department of an Indian tertiary care center, over nineteen months (Jun. 2009‒Jan. 2011). Forty-nine new patients with CLL presented during this period and were included. Twenty age- and gender-matched healthy patients served as controls, and six patients with multiple myeloma were included as positive controls. Baseline serum syndecan-1 concentrations were measured for all patients at presentation using ELISA (Diaclone, Besancon, France). At baseline, patients were divided into low (N=10), intermediate (N=18) and high (N=21) risk cohorts. Serum syndecan-1 levels in these patient subgroups were compared with clinical and laboratory parameters. Results The median syndecan-1 level in patients with CLL (73.32 ng/mL, range, 28.71‒268.0 ng/mL) was marginally higher than that in healthy patients (63.10 ng/mL, range, 55.0‒75.11 ng/mL). At presentation, syndecan-1 levels in patients with CLL correlated strongly with symptomatic disease (cytopenias, P=0.004) and higher clinical stage (Rai stage III and IV, P=0.001) markers and poorly with 2-microglobulin level (P=0.270), diffuse BM infiltration (P=0.882), and surrogate mutation status markers (CD 38, P=0.174 and ZAP-70, P=0.459). Syndecan-1 levels dichotomized by the median value were higher with progressive disease markers, e.g. shorter lymphocyte doubling time (LDT, P=0.015) and increased treatment (P=0.099). ConclusionIn CLL, serum syndecan-1 (sCD138) levels at presentation correlate with disease burden, and higher baseline levels may predict early treatment.

Squamous Metaplasia in Pleomorphic Adenoma: A Diagnostic and Prognostic Enigma

Swati Sharma,Monica Mehendiratta,Nivedita Chaudhary,Vineet Gupta,Maulshree Kohli,Anjana Arora 대한병리학회 2018 Journal of Pathology and Translational Medicine Vol.52 No.6

Pleomorphic adenoma (PA) is the most common benign salivary gland tumor. Histologically, squamous metaplasia has been reported in PA, but has rarely been documented as being extensive enough to cause significant misdiagnosis. Here, we present an unusual case of PA in a 50-yearold female patient presenting with swelling on the postero-lateral aspect of the palate for a week. Histopathologically, the tumor exhibited the features of conventional PA with extensive squamous metaplasia and giant keratotic lamellae in cyst-like areas. Such exuberant squamous metaplasia and keratin can be a diagnostic and prognostic pitfall and lead to overtreatment of the patient.

Acute lymphoblastic leukemia masquerading as acute myelofibrosis: a report of two cases and literature review

Ankur Jain,Monica Sharma,Jitender Mohan Khunger,Pooja Prasad,Dipender Kumar Gupta,Sumita Saluja,Sumita Chaudhry 대한혈액학회 2021 Blood Research Vol.56 No.1

.

Genotypic influence of a-deletions on the phenotype of Indian sickle cell anemia patients

Sanjay Pandey,Sweta Pandey,Rahasya Mani Mishra,Monica Sharma,Renu Saxena 대한혈액학회 2011 Blood Research Vol.46 No.3

Background :Some reports have shown that co-inheritance of a-thalassemia and sickle cell disease improves hematological parameters and results in a relatively mild clinical picture for patients; however, the exact molecular basis and clinical significance of the interaction between a-thalassemia and sickle cell disease in India has not yet been described. There is little agreement on the clinical effects of a-thalassemia on the phenotype of sickle cell disease. Methods :Complete blood count and red cell indices were measured by an automated cell analyzer. Quantitative assessment of hemoglobin variants HbF, HbA, HbA2, and HbS was performed by high performance liquid chromatography (HPLC). DNA extraction was performed using the phenol-chloroform method, and molecular study for common a-deletions was done by gap-PCR. Results :Out of 60 sickle cell anemia patients, the a-thalassemia genotype was found in 18 patients. Three patients had the triplicated a-genotype (Anti a-3.7 kb), and the remaining patients did not have a-deletions. This study indicates that patients with co-existing a-thalassemia and sickle cell disease had a mild phenotype, significantly improved hematological parameters, and fewer blood transfusions than the patients with sickle cell anemia without co-existing a-deletions. Conclusion :Co-existence of a-thalassemia and sickle cell anemia has significant effects on the phenotype of Indian sickle cell patients.

COVID-19 in a patient with chronic myelomonocytic leukemia: a twisting tale

Jain Ankur,Jain Aditi,Prasad Pooja,Chaudhry Sumita,Sharma Monica,Khunger Jitender Mohan,Gupta Dipender Kumar,Saluja Sumita 대한혈액학회 2020 Blood Research Vol.55 No.4

An illustrative case of B-cell prolymphocytic leukemia

Ankur Jain,JM Khunger,Pooja Prasad,Sumita Chaudhry,Monica Sharma,Dipender Kumar Gupta,Sumita Saluja 대한혈액학회 2020 Blood Research Vol.55 No.3

Psychological impact of suspension/postponement of fertility treatments on infertile women waiting during COVID pandemic

Parul Jaiswal,Reeta Mahey,Shalini Singh,Perumal Vanamail,Monica Gupta,Rohitha Cheluvaraju,J B Sharma,Neerja Bhatla 대한산부인과학회 2022 Obstetrics & Gynecology Science Vol.65 No.2

ObjectiveTo assess the psychological impact of suspension/postponement of various fertility treatments on infertile womenduring the coronavirus disease 2019 (COVID-19) pandemic. MethodsThis was a cross-sectional study conducted as an online survey among infertile women consulting either throughteleconsultation or physical consultation at a fertility clinic of a tertiary care referral unit. A validated questionnairewas given as a WhatsApp link to the women who were consulting for the resumption of services. Questions askedwere based on their socio-demographic parameters, fertility treatment at the time of suspension, anxiety (selfreported)and stress (perceived stress scale-4, PSS-4) due to delay in treatment, psychosocial effect of pandemic, andwishes regarding the resumption of fertility services. ResultsOf 430 patients who received the questionnaire, 250 completed the survey (response rate: 58%). The mean ageof participants was 29.26±4.18 years and the majority (70.4%) had lower socioeconomic status. The average PSS-4score was 7.8±0.71, and the prevalence of self-reported anxiety was 72%. Those who suffered migration during thepandemic had significantly higher PSS-4 scores, and increasing age was associated with increased self-reported anxietydue to the suspension of fertility services. The top three priorities reported were infertility and treatment delay (48.4%),job loss (19.2%), and the risk of contracting COVID-19 infection (16%). The degree of spousal support was significantlycorrelated with lower PSS-4 scores (r=-0.30, P<0.01). On multivariate logistic analysis, duration of infertility, delayin treatment due to suspension of services, and fear of COVID-19 infection were significant predictors of stress andanxiety. ConclusionThis study emphasizes the need to investigate psychosocial health and to provide psychological support to thisvulnerable population in addition to triaging fertility treatments in a phased manner.